Regulator of G protein signaling 6 (RGS6)

Regulator of G protein signaling 6 (RGS6) is a member of the RGS protein family, which accelerate the deactivation of heterotrimeric G proteins by enhancing the intrinsic GTPase activity of Gα subunits, thereby regulating G protein-coupled receptor (GPCR) signaling[2][4][5][7]. RGS6 is part of the R7 subfamily and contains both DEP (disheveled, EGL-10, pleckstrin homology) and GGL (Gγ subunit-like) domains, which control membrane targeting, stability, and subcellular localization. RGS6 modulates a wide range of cellular processes, including neuronal activity, apoptosis (cell death), mitochondrial signaling, and tumor suppression, primarily through G protein-dependent and independent pathways[2][3][7]. Its dysfunction or altered expression is associated with several diseases, notably various forms of cancer, neuropsychiatric disorders, and alcohol use disorder, making it an emerging but complex therapeutic target[2][3][4][7]. RGS6 interacts with various signaling proteins and its effects are highly tissue- and isoform-specific, complicating direct pharmacological targeting[4][7].

Other names

Regulator of G-protein signaling 6RGS6RGS 6DKFZp781D0152 (gene alias)Regulator of G protein signalling 6 (alternative British spelling)

Drugs targeting this molecule would likely act by modulating its GTPase-activating protein function, regulating GPCR signaling magnitude/duration, altering its interaction with G protein subunits, affecting subcellular localization, or influencing ROS-dependent signaling pathways